Fully human mAb program for HRV infection (AIMM Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameFully human mAb program for HRV infection (AIMM Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRhinovirus infection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAimm Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAimm Therapeutics
Active IndicationsN/A
Inactive IndicationsRhinovirus infection

Other Information

ATC CodeN/A
Related LinksN/A